ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIBGet Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 2,200 shares, a decrease of 43.6% from the December 15th total of 3,900 shares. Based on an average trading volume of 11,000 shares, the short-interest ratio is currently 0.2 days.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

A hedge fund recently raised its stake in ProShares Ultra Nasdaq Biotechnology stock. Jane Street Group LLC increased its holdings in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIBFree Report) by 8.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,803 shares of the exchange traded fund’s stock after purchasing an additional 374 shares during the period. Jane Street Group LLC owned approximately 0.35% of ProShares Ultra Nasdaq Biotechnology worth $306,000 at the end of the most recent quarter.

ProShares Ultra Nasdaq Biotechnology Stock Up 3.9 %

ProShares Ultra Nasdaq Biotechnology stock traded up $1.90 during mid-day trading on Wednesday, hitting $50.92. 7,410 shares of the stock were exchanged, compared to its average volume of 7,826. The firm’s fifty day simple moving average is $55.73 and its two-hundred day simple moving average is $61.08. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $47.19 and a 12 month high of $69.56.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The company also recently declared a dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 23rd were given a dividend of $0.3964 per share. The ex-dividend date was Monday, December 23rd. This is a boost from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.15.

About ProShares Ultra Nasdaq Biotechnology

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Featured Stories

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.